Protocol #CNP520A2202J, A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of05/01/2018 - 04/30/2025 (PI)
Novartis Pharmaceuticals Corporation
Protocol #API015A2201J, A randomized, double-blind, placebo-controlled, two cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical02/01/2018 - 08/31/2024 (PI)
Novartis Pharmaceuticals Corporation
Metformin in Alzheimers dementia Prevention (MAP)08/15/2019 - 04/30/2024 (Subcontract PI)
Trustees Of Columbia University In The City Of New York NIH NIA1R01AG062624-01
BAN2401-G000-301 A Placebo-Controlled, double Blind, parallel-group, bayseian adaptive randomization design and dose regimen finding study to evaluate safety and tolerability12/02/2019 - 12/02/2022 (PI)
Eisai, Inc
Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors12/15/2015 - 11/30/2022 (PI)
NIH/National Institute of Neurological Disorders & Stroke5U01NS093334-05
Genomics Institute of the Novartis Research Foundation--Research Contract05/01/2019 - 05/01/2020 (PI)
Novartis Institute for Functional Genomics, Inc., dba the Genomics Institute of the Novartis Research Foundation
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials ("RAmP" or 18F-AV-45-A25)03/20/2017 - 03/19/2020 (PI)
Avid Radiopharmaceuticals, Inc.
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study05/15/2019 - 02/29/2020 (Subcontract PI)
University of Southern California NIH NIA1R01AG063689-01
Alzheimer's Disease Cooperative Study - A4 Study12/01/2015 - 02/29/2020 (Subcontract PI)
University of Southern California NIH NIA5U19AG010483-26
Tau PET Imaging for the USC Alzheimer's Therapeutic Research Institute (USC ATRI) A4 Trial (“A4 TAU”)10/01/2016 - 12/31/2019 (Subcontract PI)
University of Southern California Fundation for NIH
Showing 10 of 46 results.
Show All Results
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)12/11/2015 - 12/10/2019 (Subcontract PI)
University of Southern California Eli Lilly and Co
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study11/01/2015 - 10/31/2019 (Subcontract PI)
University of Southern California Alzheimer's Assoc
A placebo-controlled, double-blind, parallel-group, bayesian adaptive randomization design and dose regimen-finding study to evaluate the safety tolerability and efficacy of BAN2401 in subjects with02/01/2013 - 12/31/2018 (PI)
Eisai, Inc
An Open label, multicenter study evaluating the imaging characteristics of a follow up F-AV-1451 scan in subjects that participated in the confirmatory cohort of FV-AV-1451-A0509/29/2016 - 09/28/2018 (PI)
Avid Radiopharmaceuticals, Inc.
Measuring Glial metabolism in repetitive brain trauma and Alzheimer's Disease08/15/2015 - 08/14/2018 (Subcontract PI)
The Brigham and Women's Hospital, Inc. DOD Army Med Resrch
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study)10/24/2016 - 06/12/2018 (PI)
Eli Lilly and Company
An open label, multicenter study, evaluating the safety and imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, subjects with Mild Cognitive Impairment, and subjects with Alzheim03/01/2014 - 05/31/2018 (PI)
Avid Radiopharmaceuticals, Inc.
A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimer's Disease (US202)11/21/2013 - 05/31/2018 (Subcontract PI)
The Regents of the University of California Toyama Chemical Co.
Protocol # 54861911ALZ2003, A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigation the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymp10/27/2017 - 05/17/2018 (PI)
Janssen Research & Development, LLC
Magnetic Resonance Spectroscopy as a Biomarker for Chronic Traumatic Encephalopathy05/01/2016 - 04/30/2018 (Multi-PI)
PI:
Robert A. Stern, PhDNIH/National Institute of Neurological Disorders & Stroke5F32NS096803-02
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo12/01/2013 - 04/30/2017 (PI)
Eli Lilly and Company
DoD Traumatic Brain Injury Research Award09/30/2013 - 09/29/2016 (PI)
Department of Defense
Amarantus LymPro Cell Cycle dysfunction Blood biomarker for AD and CTE06/16/2014 - 06/15/2016 (PI)
Amarantus Holdings, Inc.
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (Study A4)12/31/2012 - 05/31/2016 (Subcontract PI)
University of California, San Diego NIH NIA5U01AG010483-24
Risk of Cognitive Decline in Older Breast Cancer Patients10/01/2009 - 04/30/2016 (Subcontract PI)
Georgetown University NIH NCI5R01CA129769-05
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (Study A4)12/31/2012 - 04/27/2016 (Subcontract PI)
University of California, San Diego NIH NIA5U01AG010483-24
Chronic Traumatic Encephalopathy: Clinical Presentation and Biomarkers09/30/2014 - 02/29/2016 (PI)
NIH/National Institute of Neurological Disorders & Stroke2R56NS078337-04
18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects with Repetitive Brain Trauma at High Risk for Chronic Traumatic Encephalopathy03/01/2014 - 09/01/2015 (PI)
Avid Radiopharmaceuticals, Inc.
Diagnosing and Evaluating Traumatic Encephalopathy using Clinical Tests01/01/2012 - 12/31/2014 (PI)
Brainscope Company, Inc
Diagnosing and Evaluating Traumatic Encephalopathy using Clinical Tests01/01/2012 - 12/31/2014 (PI)
Brainscope Company, Inc
A Phase 3 Extension, Multicenter, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Carriers and Participated12/01/2011 - 11/30/2014 (PI)
Pfizer, Inc.
Chronic Traumatic Encephalopathy: Clinical Presentation and Biomarkers08/01/2011 - 09/29/2014 (PI)
NIH/National Institute of Neurological Disorders & Stroke5R01NS078337-03
Subclinical Hypothyroidism: Mood, Cognition and the Effect of L-Thyroxine Treatment09/30/2008 - 05/31/2014 (PI)
NIH/National Institute of Mental Health5R01MH080295-05
CONCERT PLUS: An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Laterpirdine) in Patients with Alzheimer's Disease Phase 3 Multicenter, Randomized, Placebo-Controlled,08/01/2010 - 07/31/2013 (PI)
Medivation, Inc.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Efficacy Safety Trial of Bapinevzumb (AAB-001, ELN115727) in subjects with Mild to Moderate Alzheimer Disease05/01/2011 - 04/30/2013 (PI)
Wyeth Pharmaceuticals
A Phase 3, Multicenter, Parallel-Group, Long Term Safety and Tolerabilty Treatment Trial of Bapineuzumab (AAB-001), ELN115727) in Subjects with AD Who Participated in Study ELN115727-301 or in St12/01/2009 - 04/30/2013 (PI)
Janssen Pharmaceutica (Belgium)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab11/01/2009 - 04/30/2013 (PI)
Wyeth Pharmaceuticals
ADCS Infrastructure Support01/01/2012 - 12/31/2012 (Subcontract PI)
The Regents of the University of California NIH NIA5U01AG010483-21
Multi-Centrial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old09/01/2007 - 12/31/2012 (Subcontract PI)
University of California, San Diego NIH NIA
Prevention of Alzheimer's Disease and Cognitive Decline09/01/2009 - 07/31/2012 (Subcontract PI)
Seattle Institute for Biomedical and Clinical Research NIH NIA
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer's04/01/2008 - 03/31/2012 (PI)
Elan Pharmaceuticals, Inc.
Assessment of Driving Safety in Aging, MCI and Dementia03/01/2009 - 02/29/2012 (PI)
Alzheimer's Association
Objective Biomarkers for Alzheimer's Disease in the Retina12/01/2009 - 11/30/2011 (Subcontract PI)
Mass Eye and Ear Infirmary Other Fdns/Societies
Effect of Gama Sectretase Inhibition on the Progression on AD: LY 450139 Versus Placebo, Control H6L-MC-LFAN12/01/2008 - 11/30/2011 (PI)
Eli Lilly and Company, Lilly Research Laboratories
Effect of Gamma Secretase Inhibition on the Progression on AD: LY 450139 Versus Placebo, Control H6L-MC-LFAN12/01/2008 - 11/30/2011 (PI)
Lilly Research Laboratories (Division of Eli Lilly and Company)
Driving and Dementia11/01/2004 - 10/31/2006 (PI)
Massachusetts Institute of Technology Hartford Fin Svcs Gr